Skip to content
Buy This GLP
← Research
Evidence

Do GLP-1 Drugs Prevent Heart Attacks? In People Who Already Have Heart Disease

In SELECT, 6.5% of participants assigned semaglutide had a major cardiovascular event, compared with 8.0% on placebo over a mean 39.8 months.

Editorial profile: Neil SandersBuy This GLP Editorial Team9 min read
Had a cardiovascular event, mean 39.8 monthssemaglutide 2.4 mg6.5%placebo8.0%A 1.5 point difference. 17,604 patients. Hazard ratio 0.80.Both bars drawn on the same 0–10% scale.

SELECT found fewer major cardiovascular events with semaglutide in adults with established cardiovascular disease and overweight or obesity who did not have diabetes. Over a mean follow-up of 39.8 months, 6.5% had an event on semaglutide and 8.0% on placebo[1].

The tirzepatide cardiovascular guide explains a separate trial that compared tirzepatide with dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease. The primary outcome occurred in 12.2% and 13.1%, respectively. Tirzepatide met the trial’s noninferiority criterion. Superiority was unproven [2].

The comparison with bariatric surgery comes from a matched observational cohort. The study can identify differences in outcomes between the groups. Treatment selection may still explain part of the difference[3].

In obesity-related heart failure, the SUMMIT cardiac MRI substudy found lower left ventricular mass and less fat around the heart with tirzepatide than with placebo. Those imaging results answer a different question from SELECT’s count of cardiovascular events [4].

What the trial found

SELECT enrolled 17,604 patients aged 45 or over. All had pre-existing cardiovascular disease and a BMI of 27 or greater, with no history of diabetes. They were randomized 1:1 to weekly semaglutide 2.4 mg or placebo [1]. The primary endpoint was a composite of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke.

Follow-up ran a mean of 39.8 months. The endpoint occurred in 569 of 8,803 patients on semaglutide, or 6.5%. On placebo it was 701 of 8,801, or 8.0%. The hazard ratio was 0.80 (95% CI 0.72 to 0.90, p<0.001). The mean duration of exposure to the drug was 34.2 months.

Our guide to number needed to treat reviews estimates from a broader set of cardiovascular trials. A figure from one trial applies to its outcome and follow-up period.

What it cost the people in it

Adverse events led 1,461 participants taking semaglutide (16.6%) and 718 taking placebo (8.2%) to stop the study drug permanently [1]. The evidence on how long people stay on treatment outside trials helps explain why those results and real-world refill patterns answer different questions.

What the roster can tell you about cost

Mean treatment exposure in SELECT was 34.2 months. Across the 158 injectable semaglutide prices in our comparison, the median billed rate is $186 a month. The range runs $60 to $1,299, a spread of 21.7×. If the monthly price stayed at the median, 34 months comes to $6,324. At the lowest listed rate it would be $2,040; at the highest, $44,166.

SELECT tested branded semaglutide with a target dose of 2.4 mg weekly. The analysis of higher-dose prices explains why a published starting price may cover a different dose. These roster prices include compounded preparations and cannot establish the cost of the SELECT regimen.

How to read a claim built on this trial

Check the product, target dose, follow-up period and the population studied. SELECT enrolled adults with established cardiovascular disease and overweight or obesity who did not have diabetes [1].

Use the monthly GLP-1 cost guide to compare equivalent supply periods. The guide to advertised and billed prices shows which fees and renewal terms to check before estimating a longer course.

Frequently asked

Does semaglutide reduce heart attacks and strokes?
In 17,604 patients who already had cardiovascular disease, the composite endpoint occurred in 6.5% on semaglutide against 8.0% on placebo over a mean 39.8 months — a hazard ratio of 0.80.
How many people have to take it for one to benefit?
About 67 people over roughly the trial’s follow-up period to prevent one additional cardiovascular death, nonfatal heart attack, or nonfatal stroke. The estimate uses the rounded 1.5 percentage point difference for the combined outcome.
Does the result apply to a compounded version?
The trial used brand semaglutide at 2.4 mg weekly. A cardiovascular outcome measured on one product is not automatically a property of a different preparation containing the same molecule, particularly at a dose the seller does not publish.
How many people stopped the drug?
16.6% discontinued permanently because of adverse events, against 8.2% on placebo — one in six, inside a trial, at no cost to the participant.

Sources

  1. [1] Lincoff AM, et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes New England Journal of Medicine. PMID 37952131
  2. [2] Nicholls SJ, et al. (2025). Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes The New England Journal of Medicine. PMID 41406444
  3. [3] Tseng TC, Ssu-Yu Chen S, Chen HY, Chang R (2026). Semaglutide vs Metabolic and Bariatric Surgery and Cardiovascular Outcomes in Obesity Endocrine Practice. PMID 42580629
  4. [4] Kramer CM, et al. (2025). Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy Journal of the American College of Cardiology. PMID 39566869

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence